Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP reduced its stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN) by 6.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 576,148 shares of the company’s stock after selling 42,157 shares during the quarter. Wellington Management Group LLP owned 0.47% of Mersana Therapeutics worth $824,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. State Street Corp lifted its stake in Mersana Therapeutics by 1.6% during the third quarter. State Street Corp now owns 2,725,394 shares of the company’s stock worth $5,151,000 after purchasing an additional 43,339 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Mersana Therapeutics by 18.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,351,359 shares of the company’s stock valued at $4,444,000 after buying an additional 374,460 shares during the period. SG Americas Securities LLC lifted its stake in Mersana Therapeutics by 28.7% during the 4th quarter. SG Americas Securities LLC now owns 112,291 shares of the company’s stock worth $161,000 after acquiring an additional 25,058 shares in the last quarter. Barclays PLC boosted its holdings in Mersana Therapeutics by 32.7% during the 3rd quarter. Barclays PLC now owns 494,516 shares of the company’s stock valued at $934,000 after acquiring an additional 121,799 shares during the period. Finally, FMR LLC grew its position in Mersana Therapeutics by 13.2% in the 3rd quarter. FMR LLC now owns 277,740 shares of the company’s stock valued at $525,000 after acquiring an additional 32,332 shares in the last quarter. Hedge funds and other institutional investors own 93.92% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on MRSN. Wedbush reissued an “outperform” rating and issued a $4.00 price objective on shares of Mersana Therapeutics in a research note on Monday, March 3rd. William Blair started coverage on shares of Mersana Therapeutics in a research report on Thursday, February 6th. They issued an “outperform” rating for the company. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $4.00.

Mersana Therapeutics Stock Performance

Shares of Mersana Therapeutics stock opened at $0.31 on Monday. The business has a 50-day simple moving average of $0.48 and a 200-day simple moving average of $1.29. The company has a debt-to-equity ratio of 13.35, a quick ratio of 2.35 and a current ratio of 2.35. Mersana Therapeutics, Inc. has a one year low of $0.26 and a one year high of $3.96. The company has a market cap of $38.75 million, a PE ratio of -0.51 and a beta of 1.68.

Mersana Therapeutics (NASDAQ:MRSN) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. The company had revenue of $16.36 million during the quarter, compared to the consensus estimate of $7.71 million. On average, equities research analysts forecast that Mersana Therapeutics, Inc. will post -0.62 EPS for the current fiscal year.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.